Nutriband Inc. announced that the United States Patent and Trademark Office has granted the company's request for Prioritized Examination of the U.S. patent application for "Abuse and Misuse Deterrent Transdermal System" submitted by its subsidiary, 4P Therapeutics LLC. Track One gives the company's application special status with fewer requirements than the current accelerated examination program and without having to perform a pre-examination search. However, the application still needs to be reviewed by the USPTO and the grant of Track One status does not mean that a patent will be granted. USPTO's Track One prioritized examination will normally allow the patent applicant to get a final disposition within about twelve months, although the company cannot predict the effect of the government stoppage on the timing of USPTO action. The abuse deterrent patch technology used in the Company's fentanyl transdermal system is an abuse deterrent platform technology that the Company believes can be applied to other type of pain patches and other transdermal products as well to lower the risk of abuse and accidental misuse through the use of aversive agents, creating a safer treatment option for patients.